Ascendiant Capital Initiates Coverage On GRI Bio with Buy Rating, Announces Price Target of $12
Portfolio Pulse from Benzinga Newsdesk
Ascendiant Capital has initiated coverage on GRI Bio with a Buy rating and set a price target of $12, indicating a positive outlook for the company's stock.
October 08, 2024 | 9:29 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ascendiant Capital's analyst Edward Woo has initiated coverage on GRI Bio with a Buy rating and a price target of $12, suggesting a positive short-term outlook for the stock.
The initiation of coverage with a Buy rating and a specific price target of $12 by Ascendiant Capital is likely to positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100